Drugs / Cenv3
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01718834 Comparator | Mar 2011 → Mar 2013 | — | National Liver Institute, Egypt | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cenv3 | “In the present work, we plan to study the safety and efficacy of a peptide vaccine termed Cenv3 ( C for HCV, en for envelop, v for vaccine, 3 for 3 epitopes).” NCT01718834 ↗ |
| Modality | Peptide | “Cenv3 peptide vaccine” NCT01718834 ↗ |
| Route | Subcutaneous | “HCV peptide vaccine Cenv3 will be injected subcutaneously” NCT01718834 ↗ |